GeneDx has named Linda Genen, MD, MPH, as Chief Medical Officer, a strategic hire designed to accelerate the integration of genomic testing into standard clinical workflows. Dr. Genen brings more than two decades of leadership in neonatology, payer strategy and maternal–infant health, most recently serving as CMO of ProgenyHealth. In her new role she will oversee Medical and Clinical Affairs, lead the company’s clinical strategy and drive payer engagement, partnering with innovation, commercial and policy teams. GeneDx President and CEO Katherine Stueland emphasized that Dr. Genen’s expertise in early genomic intervention will be critical as the company seeks to expand exome and genome sequencing at the point of care and reduce time to diagnosis for families with rare genetic conditions.

In 2025 GeneDx published 79 peer-reviewed studies, bringing its total to over 1,100 publications powered by GeneDx Infinity™, the world’s largest rare disease genomic dataset with nearly one million exomes and genomes. Highlights include four practice-shaping journal articles and 56 new discoveries enabled through GeneMatcher collaborations, involving 175 clinicians across 74 institutions. Landmark studies such as GUARDIAN – recognized in JAMA’s Research of the Year roundup – and SeqFirst Neo and SeqFirst Floor protocols demonstrated rapid genome sequencing as a first-tier diagnostic tool for both critically ill newborns and non-critical pediatric inpatients. These advancements have translated into 31 newly validated gene-disease associations in 2025, reinforcing GeneDx’s leadership in translating research into actionable diagnoses and supporting long-term precision health strategies.